New Drug for Hepatitis B Approved by the FDA

Medically Reviewed On: November 14, 2006

(HealthCentersOnline) - After a year-long international study, the Food and Drug Administration (FDA) has approved a new drug for the treatment of chronic hepatitis B in adults.

The drug, telbivudine (Tyzeka), is categorized by the FDA as a new molecular entity—a medication that contains an active substance that has never been approved by the FDA for marketing in the United States.

>Click here to read the whole article.

Fatty Liver and Diabetes

Swedish researchers find that many patients with a common liver disease will eventually become diabetic.

Nonalcoholic fatty liver disease (NFLD) is a buildup of fat in liver cells that is not caused by alcohol abuse. Type 2 diabetes is a metabolic disorder in which the body develops difficulty using the hormone insulin to process glucose for energy. Obesity is a major risk factor for both disorders.

The scientists found that 78 percent of the volunteers having NFLD developed diabetes or prediabetes, a condition that often leads to type 2 diabetes. They also linked NFLD, which is sometimes described as a minor condition, to a risk of developing end-stage liver disease.

They therefore recommend lifestyle modifications in all patients with NAFLD. Not only do lifestyle modifications reduce the risk of developing type 2 diabetes, intense dietary intervention may also improve liver histology in NAFLD.